medmix AG
10.34
CHF
+0.04
(+0.39%)
ISIN
CH1129677105
Return %
Stock
S&P 500
1Y
8.27
14.20
3Y
-50.05
81.12
5Y
-76.50
68.34
Capital Structure
CHF
•
in mil. unless spec.Working Capital
CHF
•
in mil. unless spec.Growth Rates
CHF
•
in mil. unless spec.Semi-annual Revenue
CHF
•
in mil. unless spec.Semi-annual Earnings Per Share
CHF
•
in mil. unless spec.Semi-annual Dividends Per Share
CHF
•
in mil. unless spec.Company Description
- CEO
- René Willi
- Full Time Employees
- 2,574
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Neuhofstrasse 20 Zug Switzerland 6340
- IPO Date
- Sep 30, 2021
- Website
- medmix.swiss
- Similar Companies
- Business
- medmix AG designs, develops, manufactures and markets high-precision delivery devices and fluid mixing systems for healthcare, consumer and industrial applications worldwide; headquartered in Zug, Switzerland, and founded in 1922 as part of legacy operations now independent following its 2021 spin-off from Sulzer AG and listing on the SIX Swiss Exchange under ticker MEDX.SW. The company operates through Healthcare and Consumer & Industrial segments, with the former encompassing Dental products such as Mixpac mixing tips, cartridges, dispensers, needles and accessories for prosthetics, restorations, anesthetics and aesthetics; Drug Delivery devices including Haselmeier self-injection pens and autoinjectors for fertility drugs, growth hormones, niche diabetes treatments, osteoporosis and rare diseases; and Surgery mixing and delivery systems for bone cement injection, hemostatic sealants and wound treatment; while Consumer & Industrial covers Industry dispensers, Mixpac cartridges and mixers for two-component adhesives and sealants in construction, transportation, electronics, infrastructure and general sectors, plus Beauty micro-brushes, mascara wands, lip gloss applicators and concealers under Geka branding. medmix maintains 14 manufacturing sites and sales offices across Europe, the Americas and Asia, employs nearly 2,700 people and holds over 900 active patents supporting its market-leading positions. Recent developments include the 2023 strategic alliance with AARDEX Group acquiring a 25% stake to enhance digital medication adherence in drug delivery via Haselmeier integration; the 2023 acquisition of Guangdong Qiaoyi Plastic Co. Ltd. to expand Beauty operations in Asia; a 2025 strategic partnership with Gurit for sustainable bonding solutions in automotive, transportation, industrial, construction and agriculture; a major new Beauty business win with facility expansions; and showcasing of the PiccoJect self-injection platform for high-viscosity drugs at 2025 conferences.
Company News
medmix Launches MIXPAC(TM) PiccoMix(TM) to Advance Efficiency and Sustainability in Dental Cementation Delivery
medmix Secures Second Consecutive CDP "A" Rating for Supplier Engagement
medmix' Drug Delivery ("Haselmeier") to Support the Development of Xeris Pharmaceuticals' XP-8121 with D-Flex(TM) Pen Injector
medmix Strengthens Profitability and Cash Flow While Advancing Growth and Efficiency Initiatives
medmix Strengthens Its Innovation Portfolio with the Launch of FleXa(TM)
medmix' Shareholders Approve All Proposals at Annual General Meeting 2026
TIME Names medmix as one of "World's Best Companies for Sustainable Growth 2026"
FY25 Results: Resilient Performance with Strong Profit Gains in Challenging Markets